Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial.
Orazio Caffo
Disclosure not yet available
Teodoro Sava
Disclosure not yet available
Umberto Basso
Disclosure not yet available
Sebastiano Buti
Disclosure not yet available
Giovanni Lo Re
Disclosure not yet available
Cosimo Sacco
Disclosure not yet available
Michele Lodde
Disclosure not yet available
Gaetano Facchini
Disclosure not yet available
Fable Zustovich
Disclosure not yet available
Alessandra Perin
Disclosure not yet available
Lucianna Russo
Disclosure not yet available
Antonello Veccia
Disclosure not yet available
Enzo Galligioni
Disclosure not yet available